Unione Europea - italiano - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - sclerosi multipla - immunosoppressori selettivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - teriflunomidum - compresse rivestite con film - teriflunomidum 14 mg, colore.: e 132, excipiens pro compresso haze. - traitement des patients adultes et des patients pédiatriques de 10 ans et plus présentant des formes récurrentes-rémittentes de sclérose en plaques (sep) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - teriflunomidum - compresse rivestite con film - comprimé pelliculé: teriflunomidum 14 mg, color.: e 132, excipiens pro compresso obducto. - traitement des patients adultes et des patients pédiatriques de 10 ans et plus présentant des formes récurrentes-rémittentes de sclérose en plaques (sep) - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - sclerosi multipla recidivante-remittente - immunosoppressori - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - sclerosi multipla recidivante-remittente - immunosoppressori selettivi immunosoppressori - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - teriflunomidum - compresse rivestite con film - teriflunomidum 14 mg, lactosum monohydricum 72.25 mg, cellulosum microcristallinum, maydis amylum, carboxymethylamylum natricum a, hydroxypropylcellulosum, silica colloidalis anhydrica, natrii stearylis fumaras, Überzug: hypromellosum, e 171, talcum, macrogolum 8000, e 132, pro compresso obducto corresp. natrium 0.56 mg. - behandlung von erwachsenen und kindern ab 10 jahren mit schubförmig-remittierender multipler sklerose (ms) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - teriflunomidum - compresse rivestite con film - teriflunomidum 14 mg, lactosum monohydricum 72.25 mg, cellulosum microcristallinum, maydis amylum, carboxymethylamylum natricum a, hydroxypropylcellulosum, silica colloidalis anhydrica, natrii stearylis fumaras, Überzug: hypromellosum, e 171, talcum, macrogolum 8000, e 132, pro compresso obducto corresp. natrium 0.56 mg. - behandlung von erwachsenen und kindern ab 10 jahren mit schubförmig-remittierender multipler sklerose (ms) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - teriflunomidum - compresse rivestite con film - teriflunomidum 14 mg, lactosum monohydricum 75.69 mg, amylum pregelificatum, cellulosum microcristallinum, hydroxypropylcellulosum, carboxymethylamylum natricum a corresp. natrium 0.21 - 0.315 mg, silica colloidalis anhydrica, magnesii stearas, hypromellosum, titanii dioxidum, e 132, glycerolum, e 133, e 129, talcum, pro compresso obducto. - behandlung von erwachsenen mit schubförmig-remittierender multipler sklerose (ms) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - teriflunomidum - compresse rivestite con film - teriflunomidum 14 mg, lactosum monohydricum 72.50 mg, cellulosum microcristallinum, maydis amylum, carboxymethylamylum natricum a corresp. natrium 0.18 - 0.28 mg, hydroxypropylcellulosum, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 1.68 mg, calcii carbonas, triacetinum, e 132, pro compresso obducto. - behandlung von erwachsenen mit schubförmig-remittierender multipler sklerose (ms) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - teriflunomidum - compresse rivestite con film - teriflunomidum 14 mg, lactosum monohydricum 47.5 mg, maydis amylum, hydroxypropylcellulosum, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 0.63 mg, talcum, calcii stearas, Überzug: hypromellosum, e 171, macrogolum 8000, e 132, pro compresso obducto. - behandlung von erwachsenen mit schubförmig-remittierender multipler sklerose (ms) - synthetika